The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism
Mary Ann Anderson(The Royal Melbourne Hospital), Andrew W. Roberts(The Royal Melbourne Hospital), Anthony Letai(Dana-Farber Cancer Institute), Joshua Fein(Dana-Farber Cancer Institute), Constantine S. Tam(The Alfred Hospital), David C.S. Huang(Indonesia International Institute for Life Sciences), Matthew S. Davids(Dana-Farber Cancer Institute), Jing Deng(Guangdong Provincial Center for Disease Control and Prevention), John F. Seymour(The Royal Melbourne Hospital), Éric Ghigo(Walter and Eliza Hall Institute of Medical Research), Sari L. Heitner Enschede(AbbVie (United States)), David Westerman(University of Melbourne), David Segal(Walter and Eliza Hall Institute of Medical Research), Su Young Kim(National Institutes of Health), Ian J. Majewski(The University of Melbourne), Lijian Yu, Jennifer R. Brown(Dana-Farber Cancer Institute)
Cited by 329
Related Papers
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k